RXRX insider trading
HealthcareRECURSION PHARMACEUTICALS, INC.: insider trade history from SEC Form 4 filings.
About RECURSION PHARMACEUTICALS, INC.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Company website: www.recursion.com
RXRX insider activity at a glance
FilingIQ tracks 1,158 insider transactions for RXRX in filings since Apr 19, 2021. The most recent transaction is dated Oct 1, 2026.
Across the full history, 29 open-market purchases
and 421 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RXRX insider trades is 51.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RXRX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding RXRX
Frequently asked
- How many insider trades does FilingIQ track for RXRX?
- FilingIQ tracks 1,158 Form 4 insider transactions for RXRX (RECURSION PHARMACEUTICALS, INC.), covering filings from Apr 19, 2021 onwards. 9 of those are dated within the last 90 days.
- Are RXRX insiders net buyers or net sellers?
- Across the full Form 4 history for RXRX, 29 transactions (3%) were open-market purchases and 421 (36%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RXRX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is RXRX in?
- RECURSION PHARMACEUTICALS, INC. (RXRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.76B.
Methodology & sources
Every RXRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.